Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300032 | 0.88 | CYP2C19 (0.41) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL9129381 | 0.83 | ALDH1A1 (0.44) | LMNAALDH1A1ALOX15 | |
| SCHEMBL22299925 | 0.83 | TSHR (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL15635387 | 0.81 | LMNA (0.43) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL5987635 | 0.79 | TSHR (0.46) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL5987683 | 0.79 | TSHR (0.46) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL7603104 | 0.79 | TSHR (0.46) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL27743278 | 0.78 | CYP2C19 (0.38) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL18331644 | 0.77 | CYP2C19 (0.35) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL13647279 | 0.77 | MMP1 (0.50) | MEN1CYP2C19RECQLKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190875-A1 | SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF | CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| EP-4282867-A1 | INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190875-A1 | SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF | GHSR, GHRHR, NR3C2 | MEN1 306/4885CYP2C19 764/4885RECQL 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.